RecruitingNot ApplicableNCT06506942
The TRICURE EFS Study
The TRICURE EFS TRiCares Topaz Transfemoral TRICUspid Heart Valve REplacement System Early Feasibility Study
Sponsor
TRiCares
Enrollment
15 participants
Start Date
Sep 11, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Prospective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Adult patients
- Tricuspid regurgitation grade 3 (severe) on a scale of 0 (none) to 5 (torrential)
- Institutional Heart Team evaluates patient as being at increased operative risk
Exclusion Criteria4
- Patient in need of emergent intervention
- Patient who is hemodynamically unstable
- Anatomical contraindications for implantation with study device
- Patient who is currently participating in another clinical investigation where the primary endpoint was not reached yet
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICETranscatheter Tricuspid Valve Replacement
Replacement of the tricuspid valve through a transcatheter approach
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06506942
Related Trials
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731151 locations
Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease
NCT060726901 location
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
NCT054231582 locations
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT0631003137 locations
The Leadless AV Versus DDD Pacing Study
NCT054983761 location